You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 4, 2024

Claims for Patent: 10,583,205


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,583,205
Title:Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Abstract:Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500.
Inventor(s):Freeman Matthew S., Driehuys Bastiaan
Assignee:Duke University
Application Number:US16653082
Patent Claims: 1. A flow-through optical spin exchange hyperpolarized gas production system for producing hyperpolarized gas comprising:a pre-saturation chamber comprising an Area Ratio (AR) of between 20 and 500, wherein the pre-saturation chamber comprises alkali metal therein;a heat source in communication with the pre-saturation chamber configured to heat the pre-saturation chamber to between 140 Celsius and 300 Celsius;a flow-through optical pumping cell in fluid communication with the pre-saturation chamber;{'sup': '129', 'a gas mixture comprising Xe gas in the optical pumping cell; and'}a heat source in communication with the optical pumping cell, wherein the heat source is configured to heat the optical pumping cell to a temperature that is less than the pre-saturation chamber,{'sup': 129', '129, 'wherein the system hyperpolarizes the Xe gas in the optical pumping cell and provides at least one bolus amount of the hyperpolarized Xe gas for inhalation delivery to a patient.'}2. The system of claim 1 , further comprising an accumulator in fluid communication with the optical pumping and located downstream of the optical pumping cell claim 1 , wherein the accumulator collects the at least one bolus amount of the hyperpolarized Xe gas.3. The system of claim 2 , further comprising a bag that is releasably coupled to the accumulator and that holds the at least one bolus amount of the hyperpolarized gas for inhalation delivery to the patient.4. The system of claim 3 , wherein the at least one bolus amount of hyperpolarized Xe gas in the bag has sufficient hyperpolarization level when dispensed to the patient in an MRI scanner to obtain MR spectroscopy data and/or MRI image data of at least one of pulmonary ventilation or gas exchange in one or more lungs of the patient.5. The system of claim 1 , wherein the AR of the pre-saturation chamber is between 20 and 200.6. The system of claim 1 , wherein a new and/or previously unused pre-saturation chamber comprises rubidium (Rb) in an amount between 0.5 and 5 grams.7. The system of claim 1 , wherein the pre-saturation chamber is a first pre-saturation chamber and has axially spaced apart first and second end portions that releasably and sealably engage a flow manifold that resides upstream of the optical pumping cell claim 1 , wherein the first and second end portions are detachable from the flow manifold of the hyperpolarized gas production system claim 1 , wherein the flow manifold releasably and sealably engages first and second end portions of a second pre-saturation chamber having a common size and shape as the first pre-saturation chamber claim 1 , wherein the second pre-saturation chamber is filled with alkali metal to thereby allow for a plurality of pre-saturation chambers to be used with the same optical pumping cell over production cycles to provide at least one bolus amount of the hyperpolarized Xe gas.8. The system of claim 1 , further comprising a pressurized flow manifold that resides upstream of the optical pumping cell and maintains a gas flow path into the optical pumping cell at a defined pressure claim 1 , wherein the pre-saturation chamber is a detachable pre-saturation chamber that claim 1 , in operation claim 1 , is interchangeably claim 1 , sealably attached to the pressurized flow manifold with at least one quick connect and/or valve.9. The system of claim 1 , further comprising a voltage source that is configured to generate an electrical field between about 2 kV/cm to about 20 kV/cm in or about the optical pumping cell claim 1 , wherein the electrical field is configured to attract charged nanoclusters.10. The system of claim 1 , further comprising:a control circuit in communication with the optical pumping cell;a probe laser configured to project an off-resonance probe beam across the optical pumping cell; anda detector in communication with the probe laser and control circuit, positioned across from the probe laser on an opposing side of the optical pumping cell, wherein the control circuit is configured to identify attenuation of a signal from the probe beam that is associated with production of nanoclusters in the gas flow stream in the optical pumping cell.11. The system of claim 1 , wherein the pre-saturation chamber is external to the optical pumping cell and is upstream of an inlet port of the optical pumping cell.12. The system of claim 8 , wherein the pre-saturation chamber comprises threads claim 8 , a valve and/or a nozzle and is detachably claim 8 , sealably attached to the flow manifold.13. The system of claim 1 , further comprising an accumulator in fluid communication with and downstream of the optical pumping cell claim 1 , wherein claim 1 , in operation claim 1 , the hyperpolarized Xe gas is exposed to temperatures below its freezing point and collected as a frozen product at the accumulator.14. The system of claim 13 , further comprising a magnetic yoke of permanent magnets surrounding a portion of a cold finger of the accumulator.15. The system of claim 1 , wherein the system further comprises a probe laser positioned along one long side of the optical pumping cell claim 1 , wherein the probe laser directs a probe beam across the optical cell in a direction that is orthogonal to a direction of a spin-exchange optical pumping laser beam.16. The system of claim 15 , further comprising regional heat sources for defining an optical window on each side of the optical pumping cell for the probe laser to project across without attenuation due to alkali metal deposited onto an inner surface of the cell under the optical window.17. A flow-through optical spin exchange hyperpolarized gas production system for producing hyperpolarized gas comprising:a pre-saturation chamber comprising an Area Ratio (AR) of between 20 and 500, wherein the pre-saturation chamber comprises alkali metal therein;a heat source in communication with the pre-saturation chamber configured to heat the pre-saturation chamber to between 140 Celsius and 300 Celsius;a flow-through optical pumping cell in fluid communication with the pre-saturation chamber;{'sup': '129', 'a gas mixture comprising Xe gas in the optical pumping cell;'}a heat source in communication with the optical pumping cell, wherein the heat source is configured to heat the optical pumping cell to a temperature that is less than the pre-saturation chamber;a control circuit in communication with the optical pumping cell;a probe laser configured to project an off-resonance probe beam across the optical pumping cell, wherein the probe laser has a wavelength that generates a blue laser beam; anda detector in communication with the probe laser and control circuit, positioned across from the probe laser on an opposing side of the optical pumping cell, wherein attenuation of a signal from the probe beam is associated with production of nanoclusters in the gas flow stream in the optical pumping cell,{'sup': 129', '129, 'wherein the system hyperpolarizes the Xe gas in the optical pumping cell and provides at least one bolus amount of the hyperpolarized Xe gas for inhalation delivery to a patient.'}18. The system of claim 17 , wherein the probe laser has a wavelength of about 450 nm.19. The system of claim 17 , wherein the pre-saturation chamber is external to the optical pumping cell and is upstream of an inlet port of the optical pumping cell.20. The system of claim 17 , wherein the at least one bolus amount of hyperpolarized Xe gas has sufficient hyperpolarization level when dispensed to the patient in an MRI scanner to obtain MR spectroscopy data and/or MRI image data of at least one of pulmonary ventilation or gas exchange in one or more lungs of the patient.21. The system of claim 17 , further comprising an accumulator in fluid communication with the optical pumping and located downstream of the optical pumping cell claim 17 , wherein the accumulator collects the at least one bolus amount of the hyperpolarized Xe gas.22. The system of claim 21 , further comprising a bag that is releasably coupled to the accumulator and that holds the at least one bolus amount of the hyperpolarized gas for inhalation delivery to the patient.23. The system of claim 21 , wherein claim 21 , in operation claim 21 , the hyperpolarized Xe gas is exposed to temperatures below its freezing point and collected as a frozen product at the accumulator claim 21 , and wherein the system further comprises a magnetic yoke of permanent magnets surrounding a portion of a cold finger of the accumulator.24. An optical spin exchange hyperpolarized gas production system for producing hyperpolarized gas comprising:a pre-saturation chamber comprising alkali metal;a heat source in communication with the pre-saturation chamber configured to heat the pre-saturation chamber to between 140 Celsius and 300 Celsius;an optical pumping cell in fluid communication with the pre-saturation chamber;{'sup': '129', 'a gas mixture comprising Xe gas in the optical pumping cell; and'}a nanocluster detection system in communication with the optical pumping cell, wherein the nanocluster detection system comprises one or more of: (i) a fluorescence spectroscopy detector, (ii) an IR (infrared) camera to observe plumes, and/or (iii) a probe laser and associated detector,{'sup': 129', '129, 'wherein the system hyperpolarizes the Xe gas in the optical pumping cell and provides at least one bolus amount of the hyperpolarized Xe gas for inhalation delivery to a patient.'}25. The system of claim 24 , wherein the pre-saturation chamber is external to and upstream of an inlet port of the optical pumping cell.26. The system of claim 24 , wherein the pre-saturation chamber comprises threads claim 24 , a valve and/or a nozzle and is detachably claim 24 , sealably attached to the flow manifold.27. The system of claim 24 , wherein the at least one bolus amount of hyperpolarized Xe gas has sufficient hyperpolarization level when dispensed to the patient in an MRI scanner to obtain MR spectroscopy data and/or MRI image data of at least one of pulmonary ventilation or gas exchange in one or more lungs of the patient.28. The system of claim 24 , further comprising an accumulator in fluid communication with the optical pumping and located downstream of the optical pumping cell claim 24 , wherein the accumulator collects the at least one bolus amount of the hyperpolarized Xe gas.29. The system of claim 28 , further comprising a bag that is releasably coupled to the accumulator and that holds the at least one bolus amount of the hyperpolarized gas for inhalation delivery to the patient.30. The system of claim 28 , wherein claim 28 , in operation claim 28 , the hyperpolarized Xe gas is exposed to temperatures below its freezing point and collected as a frozen product at the accumulator claim 28 , and wherein the system further comprises a magnetic yoke of permanent magnets surrounding a portion of a cold finger of the accumulator.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.